Differentiation of embryonic stem cells into hepatocytes by transcription factors that promote hepatocyte differentiation

通过促进肝细胞分化的转录因子将胚胎干细胞分化为肝细胞

基本信息

  • 批准号:
    16590577
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2004
  • 资助国家:
    日本
  • 起止时间:
    2004 至 2005
  • 项目状态:
    已结题

项目摘要

Background & Aims : To apply embryonic stem (ES) cells into liver failure, we tried to promote ES cells to differentiate into hepatoccytes. Methods : Only hepatocytes have urea cycle and gluconeogenesis. It was expected that other cells died while hepatocytes differentiated from ES cells survived if ES cells were cultured in the medium with the products of the urea cycle and gluconeogenesis, and added with their substrates. We, thus, tried to invest a medium without arginine and glucose, added with ornithine and galactose (HSM). RT-PCR was performed to detect the expression of albumin and glucose-6-phospodiesterase (G6PD). Indocyanin green (ICG) is taken up by exclusively hepatocytes. The cells positive for ICG are hepatocytes. ICG was, then, applied to the medium to further confirm hepatocytes. CCCAT/enhancer binding protein (C/EBP) α and C/EBP β are liver enriched transcription factors, and promote hepatocyte differentiation. They were expected to promote differentiation of ES cells … More into hepatocytes. Adenovirus vector expressing C/EBP α or C/EBP β was constructed with in vitro ligation. Western blot was performed to confirm that the adenovirus vectors really expressed C/EBP α or C/EBP β. Results : The number of cells cultivated in HSM decreased to 3% compared to that of cells in control medium. RT-PCR revealed that the surviving cells expressed albumin and G6PD. When added with ICG, the surviving cells were positive with ICG, and the number of positive cells was larger than that of cells in control medium. These data indicated that ES cells differentiated into hepatocytes in HSM more effectively than in control medium. Western blot revealed that the adenoviruses really expressed (C/EBP) α or C/EBP β. Conclusion : HSM promoted the differentiation of ES cells into hepatocytes. The adenoviruses were constructed to express C/EBP α or C/EBP β. Our next experiment was to infect ES cells with the adenoviruses to promote hepatocyte differentiation of ES cells more effectively. Less
背景与目的:为了将胚胎干细胞(ES细胞)应用于肝衰竭的治疗,我们尝试促进ES细胞向肝细胞分化。方法:只有肝细胞具有尿素循环和尿素合成功能。如果将ES细胞培养在含有尿素循环和胚胎异生产物的培养基中,并加入它们的底物,则预期其他细胞死亡,而从ES细胞分化的肝细胞存活。因此,我们试图投资一种培养基,没有精氨酸和葡萄糖,添加了鸟氨酸和半乳糖(HSM)。RT-PCR检测白蛋白和葡萄糖-6-磷酸二酯酶(G6 PD)的表达。吲哚菁绿色(ICG)仅由肝细胞摄取。ICG阳性细胞为肝细胞。然后,将ICG应用于培养基以进一步确认肝细胞。CCCAT/增强子结合蛋白(C/EBP)α和C/EBP β是肝脏富集的转录因子,促进肝细胞分化。预期它们能促进ES细胞的分化 ...更多信息 转化成肝细胞体外连接法构建C/EBP α和C/EBP β的腺病毒载体。Western blot检测腺病毒载体是否真的表达C/EBP α或C/EBP β。结果:与对照培养基相比,在HSM中培养的细胞数量减少至3%。RT-PCR显示存活细胞表达白蛋白和G6 PD。加入ICG后,存活细胞呈ICG阳性,阳性细胞数明显多于对照组。这些数据表明,ES细胞分化成肝细胞在HSM比在对照培养基中更有效。Western blot结果显示腺病毒真核表达(C/EBP)α或C/EBP β。结论:HSM可促进ES细胞向肝细胞分化。构建表达C/EBP α或C/EBP β的腺病毒。我们的下一步实验是用腺病毒感染ES细胞,以更有效地促进ES细胞的肝细胞分化。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TOMIZAWA Minoru其他文献

TOMIZAWA Minoru的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TOMIZAWA Minoru', 18)}}的其他基金

Development of transplantation of hepatocytes produced from iPS cells to liver failure
iPS细胞产生的肝细胞移植治疗肝衰竭的进展
  • 批准号:
    23591002
  • 财政年份:
    2011
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hepatocyte differentiation aiming at transplantation of ES cells for hepatic insufficiency
肝细胞分化,旨在移植ES细胞治疗肝功能不全
  • 批准号:
    19590748
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of CCAT/enhancer binding protein (C/EBP) α and C/EBP β in carcinogenesis. of hepatoblastoma and differentiation of hepatoblast.
CCAT/增强子结合蛋白 (C/EBP) α 和 C/EBP β 在肝母细胞瘤发生和肝母细胞分化中的作用。
  • 批准号:
    14570726
  • 财政年份:
    2002
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Pluripotent stem cell derived hepatocytes for liver failure (PUSH for LIFE)
多能干细胞衍生的肝细胞治疗肝衰竭(PUSH for LIFE)
  • 批准号:
    MR/Z503940/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
衰老肝细胞介导急性肝衰竭中免疫细胞的重编程
  • 批准号:
    10679938
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
I-Corps: Medical device to treat liver failure
I-Corps:治疗肝衰竭的医疗设备
  • 批准号:
    2348688
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Standard Grant
Development of a Novel Liver Failure Therapy Based on Improvement of Energy Status of Hepatocytes by Oxygenated Perfusion
开发基于氧合灌注改善肝细胞能量状态的新型肝衰竭疗法
  • 批准号:
    23K08166
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel regenerative therapy for liver failure with skeletal myoblast cell sheet transplantation
骨骼肌成肌细胞片移植治疗肝衰竭的新型再生疗法
  • 批准号:
    22K08800
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hepatocytes Encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute Liver failure in Paediatric patients (HELP)
将间充质基质细胞封装在藻酸盐微珠中的肝细胞用于治疗儿科患者的急性肝衰竭(HELP)
  • 批准号:
    MR/V038583/1
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
New treatment methods for liver failure by human iPS cells
人类iPS细胞治疗肝衰竭的新方法
  • 批准号:
    22K08735
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Checkpoint Inhibitors to Restore Monocyte/Macrophage Function in Liver Failure
检查点抑制剂可恢复肝衰竭患者的单核细胞/巨噬细胞功能
  • 批准号:
    MR/W015412/1
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
  • 批准号:
    10421290
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Development of the innovative treatment using self iPS cell for acute liver failure
开发利用自身 iPS 细胞治疗急性肝衰竭的创新疗法
  • 批准号:
    21K08685
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了